Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 29; no. 36; p. 4845
Main Authors Monk, Bradley J, Pandite, Lini N
Format Journal Article
LanguageEnglish
Published United States 20.12.2011
Subjects
Angiogenesis Inhibitors - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Female
Humans
Pyrimidines - administration & dosage
Quinazolines - administration & dosage
Sulfonamides - administration & dosage
Uterine Cervical Neoplasms - drug therapy
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2011.38.8777